https://orcid.org/0000-0002-6556-4128
Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Bing Cao, Shanshan Gu, Zhisen Shen, Yuna Zhang, Yiming Shen & Hang Chen. (2023) Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system. Expert Opinion on Drug Safety 0:0, pages 1-7.
Read now
Read now
Shu-zhi Wu & Linglong Chen. (2022) Efficacy and safety of ubrogepant for migraine: a meta-analysis of randomized controlled studies. International Journal of Neuroscience 0:0, pages 1-7.
Read now
Read now
Silvia Benemei, Enrico Bentivegna & Paolo Martelletti. (2022) Positioning the new drugs for migraine. Expert Opinion on Drug Metabolism & Toxicology 18:1, pages 1-3.
Read now
Read now
Karissa Johnston, Evan Popoff, Alison Deighton, Parisa Dabirvaziri, Linda Harris, Alexandra Thiry, Robert Croop, Vladimir Coric, Gilbert L’Italien & James Moren. (2022) Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Review of Pharmacoeconomics & Outcomes Research 22:1, pages 155-166.
Read now
Read now
Sui-yi Xu, Hui-juan Li, Jing Huang, Xiu-ping Li & Chang-xin Li. (2021) Migraine with Brainstem Aura Accompanied by Disorders of Consciousness. Journal of Pain Research 14, pages 1119-1127.
Read now
Read now
Paolo Martelletti & Martina Curto. (2021) Unmet needs for migraine. Current Medical Research and Opinion 37:11, pages 1957-1959.
Read now
Read now
Peer Tfelt-Hansen. (2021) Pharmacological strategies to treat attacks of episodic migraine in adults. Expert Opinion on Pharmacotherapy 22:3, pages 305-316.
Read now
Read now
Abimael González-Hernández, Miguel Condés-Lara, Enrique García-Boll & Carlos M. Villalón. (2021) An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies. Expert Opinion on Drug Metabolism & Toxicology 17:2, pages 179-199.
Read now
Read now
Wade Cooper, Erin Gautier Doty, Helen Hochstetler, Ann Hake & Vincent Martin. (2020) The current state of acute treatment for migraine in adults in the United States. Postgraduate Medicine 132:7, pages 581-589.
Read now
Read now
Articles from other publishers (15)
Richard B. Lipton, Janette Contreras-De Lama, Daniel Serrano, Ella Engstrom, Nicolai D. Ayasse, Weijie Poh, François Cadiou & Aubrey Manack Adams. (2023) Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE. Neurology and Therapy.
Crossref
Crossref
Richard B. Lipton, Rashmi B. Halker Singh, Dennis A. Revicki, Sihui Zhao, Anand R. Shewale, Jordan E. Lateiner & David W. Dodick. (2022) Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials. The Journal of Headache and Pain 23:1.
Crossref
Crossref
Dilara Onan, William Wells-Gatnik & Paolo Martelletti. (2022) Reaching the Nadir of Medication Overuse in Chronic Migraine. International Journal of Environmental Research and Public Health 19:22, pages 14696.
Crossref
Crossref
I. S. Yadgarov, E. G. Filatova, V. L. Golubev & A. V. Berdnikova. (2022) Relief of migraine attack — hepants. Russian neurological journal 27:3, pages 5-10.
Crossref
Crossref
Abhigyan Datta, Sahil Gupta, Shashi Maryala, Vikram Aggarwal, Pooja Chopra & Sameer Jain. (2022) Erenumab for episodic migraine. Pain Management 12:5, pages 587-594.
Crossref
Crossref
Andrew M. Blumenfeld, Kerry Knievel, Aubrey Manack Adams, Lawrence Severt, Matthew Butler, Hongxin Lai & David W. Dodick. (2021) Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials. Advances in Therapy 39:1, pages 692-705.
Crossref
Crossref
Matilde Capi, Valerio De Angelis, Donatella De Bernardini & Paolo Martelletti. 2022. Novel Synthetic Drugs in Migraine. Novel Synthetic Drugs in Migraine
67
72
.
Martina Curto & Luana Lionetto. 2022. Novel Synthetic Drugs in Migraine. Novel Synthetic Drugs in Migraine
43
50
.
Yee Jung Kim & Richard D. Granstein. (2021) Roles of calcitonin gene-related peptide in the skin, and other physiological and pathophysiological functions. Brain, Behavior, & Immunity - Health 18, pages 100361.
Crossref
Crossref
Shivang Joshi, Stewart J. Tepper, Sylvia Lucas, Soeren Rasmussen & Rob Nelson. (2021) A narrative review of the importance of pharmacokinetics and drug–drug interactions of preventive therapies in migraine management. Headache: The Journal of Head and Face Pain 61:6, pages 838-853.
Crossref
Crossref
Matilde Capi, Valerio De Angelis, Donatella De Bernardini, Ottavia De Luca, Fabiola Cipolla, Luana Lionetto, Maurizio Simmaco & Paolo Martelletti. (2021) CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine. Journal of Clinical Medicine 10:7, pages 1429.
Crossref
Crossref
Chia‐Chun Chiang, Karissa N. Arca, Rachel B. Dunn, Marlene E. Girardo, Jaxon K. Quillen, David W. Dodick & Amaal J. Starling. (2021) Real‐world efficacy, tolerability, and safety of ubrogepant. Headache: The Journal of Head and Face Pain 61:4, pages 620-627.
Crossref
Crossref
Dong Kyoung Ha, Min Ji Kim, Nayoung Han, Jae-Hwan Kwak & In-hwan Baek. (2021) Comparative Efficacy of Oral Calcitonin-Gene–Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis. Clinical Drug Investigation 41:2, pages 119-132.
Crossref
Crossref
Amber N. Edinoff, C. Austin Casey, Marc A. Colon, Alexa R. Zaheri, Courtney M. Gregoire, Margaret M. Bourg, Alan D. Kaye, Jessica S. Kaye, Adam M. Kaye, Rachel J. Kaye, Sridhar R. Tirumala, Omar Viswanath & Ivan Urits. (2021) Ubrogepant to Treat Acute Migraine in Adults. Neurology International 13:1, pages 32-45.
Crossref
Crossref
Alok Singh, Dhyuti Gupta & Ajaya Kumar Sahoo. (2020) Acute Migraine: Can the New Drugs Clinically Outpace?. SN Comprehensive Clinical Medicine 2:8, pages 1132-1138.
Crossref
Crossref